Position in CLLS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$9,844,503
-$557,855 QoQ
Shares Held
3,281,501
0.0% QoQ
Ownership
3.26%
of shares outstanding
% of Portfolio
5.54%
of 13F equity value
Holder Rank
#1
of 27 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CLLS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026B Group, Inc. holds $172,531,686 across 17 Biotechnology names. CLLS ranks #7 (5.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ADMA |
Adma Biologics, Inc.
|
3,262,542 | $27,307,476 | |
| 2 | PALI |
Palisade Bio, Inc.
|
11,414,285 | $23,855,855 | |
| 3 | NRXP |
NRX Pharmaceuticals, Inc.
|
4,091,767 | $16,735,327 | |
| 4 | FTH |
Faeth Therapeutics, Inc.
|
610,169 | $15,254,225 | |
| 5 | TSHA |
Taysha Gene Therapies, Inc.
|
1,800,556 | $12,261,786 | |
| 6 | PRAX |
Praxis Precision Medicines, Inc.
|
33,237 | $11,127,415 | |
| 7 | CLLS |
Cellectis S.A.
This page
|
3,281,501 | $9,844,503 | |
| 8 | ZLAB |
Zai Lab Ltd
|
450,646 | $8,562,274 |
All Filings in CLLS
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $9,844,503 | 3,281,501 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $10,402,358 | 3,281,501 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $15,882,464 | 3,281,501 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $9,352,277 | 3,281,501 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $4,966,164 | 3,256,501 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $4,038,061 | 3,256,501 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $5,546,701 | 3,081,501 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||